Skip to content
Research Article Open access CC BY 4.0

Possible Mechanisms of Drugs Used in the Treatment of COVID-19: A Pharmacological Perspective

Ravindra Babu Pingili, Tanvija Kodali, Naveen Babu Kilaru, Vijaya R. Dirisala, Siva Reddy Challa, Akhila Kondru, Sirisha Koppula, Sravani Melike, Vyshnavi Toleti, Vara Prasad Saka

Journal of Pharmaceutical Research International · pp. 43–57 · Published 10 Jan 2022

10.9734/jpri/2022/v34i1B35352

Abstract

Coronaviruses are a type of virus that can infect both animals and humans. Coronaviruses are divided into thirty-nine species and twenty-seven subgenus in the family Coronaviridae, according to the current classification. Seven of these are known to induce respiratory infections, while four others can cause cold-like symptoms on a regular basis. SARS CoV, MERS-CoV, and SARS CoV-2 infection are three examples of viral rebound. They are to blame for SARS, MERS, and the most recent Coronavirus epidemic discovered in 2019. (COVID-19). The World Health Organization declared the respiratory sickness caused by the SARS-CoV-2 infection to be a pandemic (WHO). For this COVID-19, there are currently no properly shown managements. The virology of SARS-CoV-2 has yielded a large number of therapeutic targets. Remdesivir appears to be the most promising treatment. Currently, COVID-19 is treated with Dexamethasone, Tocilizumab, Remdesivir, Chloroquine and Hydroxychloroquine, Lopinavir, Favipiravir, Niclosamide, Azithromycin, Sarilumab, Baricitinib, Ruxolitinib, Ribavarin, Nitazoxanide, Umifenovir, Camostat, Ciclesonide, Darun They exert their effects through blocking receptors such as IL 6, TMPRSS2, CD147, and AAKI, as well as RNA dependent RNA polymerase, membrane fusion, endocytosis, and proteolysis. The authors of this study looked at the available literature on the SARS-CoV-2 virus and the COVID-19 virus in terms of therapeutic evidence. This in-depth and thorough examination provides an excellent overview of the most up-to-date information on the medications used to treat COVID-19.

COVID-19 remdesivir coronavirus favipiravir azithromycin

References (74)

  1. 1 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor [DOI]
  2. 2 Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding [DOI]
  3. 3 Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review [DOI]
  4. 4 Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) [DOI]
  5. 5 The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro [DOI]
  6. 6 Coronavirus Disease 2019 (COVID-19): A Perspective from China [DOI]
  7. 7 Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury [DOI]
  8. 8 Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality [DOI]
  9. 9 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis [DOI]
  10. 10 Molecular immune pathogenesis and diagnosis of COVID-19 [DOI]
  11. 11 Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 [DOI]
  12. 12 Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial [DOI]
  13. 13 Baricitinib as potential treatment for 2019-nCoV acute respiratory disease [DOI]
  14. 14 Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial [DOI]
  15. 15 COVID-19: combining antiviral and anti-inflammatory treatments [DOI]
  16. 16 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response [DOI]
  17. 17 The epidemiology, diagnosis and treatment of COVID-19 [DOI]
  18. 18 FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome [DOI]
  19. 19 Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? [DOI]
  20. 20 Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs [DOI]
  21. 21 Treatment options for COVID-19: The reality and challenges [DOI]
  22. 22 Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study [DOI]
  23. 23 Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact [DOI]
  24. 24 Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol [DOI]
  25. 25 Arbidol: A Broad-Spectrum Antiviral Compound that Blocks Viral Fusion [DOI]
  26. 26 The biology and toxicology of molluscicides, bayluscide [DOI]
  27. 27 Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay [DOI]
  28. 28 Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.
  29. 29 SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus [DOI]
  30. 30 Tocilizumab for the treatment of severe coronavirus disease 2019 [DOI]
  31. 31 Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019 [DOI]
  32. 32 Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia [DOI]
  33. 33 The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses [DOI]
  34. 34 Macrolide Therapy in Respiratory Viral Infections [DOI]
  35. 35 Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19 [DOI]
  36. 36 Medical treatment options for COVID-19 [DOI]
  37. 37 Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far? [DOI]
  38. 38 Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors against the Initial Autocleavage in Gag-Pol Polyprotein Processing [DOI]
  39. 39 Cardiac arrest caused by nafamostat mesilate [DOI]
  40. 40 Safety of baricitinib in East Asian patients with moderate‐to‐severe active rheumatoid arthritis: An integrated analysis from clinical trials [DOI]
  41. 41 Palmoplantar Pustulosis-like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis [DOI]
  42. 42 Ruxolitinib treatment for SR-aGVHD in patients with EBV-HLH undergoing allo-HSCT [DOI]
  43. 43 Laboratory Diagnosis of COVID-19: Current Issues and Challenges [DOI]
  44. 44 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [DOI]
  45. 45 Pathogenesis of COVID-19 from a cell biology perspective [DOI]
  46. 46 Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial [DOI]
  47. 47 SARS-CoV-2 invades host cells via a novel route: CD147-spike protein [DOI]
  48. 48 The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15 [DOI]
  49. 49 Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial [DOI]
  50. 50 The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19 [DOI]
  51. 51 Dexamethasone in Hospitalized Patients with Covid-19 [DOI]
  52. 52 Remdesivir for the Treatment of Covid-19 — Final Report [DOI]
  53. 53 Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 [DOI]
  54. 54 American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 1 [DOI]
  55. 55 Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial [DOI]
  56. 56 American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 2 [DOI]
  57. 57 Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study [DOI]
  58. 58 The Pathogenesis of Coronavirus Disease 2019 (COVID‐19): Evaluation and Prevention [DOI]
  59. 59 Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19 [DOI]
  60. 60 FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy [DOI]
  61. 61 Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines [DOI]
  62. 62 Lack of antiviral activity of darunavir against SARS-CoV-2 [DOI]
  63. 63 Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19 [DOI]
  64. 64 Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis [DOI]
  65. 65 Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action [DOI]
  66. 66 Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19 [DOI]
  67. 67 Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy [DOI]
  68. 68 Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19 [DOI]
  69. 69 Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19 [DOI]
  70. 70 SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus [DOI]
  71. 71 Treatment with Hydroxychloroquine vs Hydroxychloroquine + Nitazoxanide in COVID-19 patients with risk factors for poor prognosis: A structured summary of a study protocol for a randomised controlled trial [DOI]
  72. 72 COVID-19: therapeutic approaches description and discussion [DOI]
  73. 73 Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center [DOI]
  74. 74 Energetics Based Modeling of Hydroxychloroquine and Azithromycin Binding to the SARS-CoV-2 Spike (S)Protein - ACE2 Complex [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.